Sorafenib for relapsed FLT3‐ITD‐positive acute myeloid leukemia postallogeneic stem cell transplantation presenting as leukemia cutis

Abstract Relapse of FLT3‐mutated acute myeloid leukemia (AML) following allogeneic stem cell transplantation is associated with poor survival. The clinical utility of sorafenib monotherapy in this setting is described in a patient presenting as leukemia cutis.

Bibliographic Details
Main Authors:	Rachel Brodie, Stephen E. Langabeer, John Quinn, Máirín E. McMenamin, Patrick J. Hayden
Format:	Article
Language:	English
Published:	Wiley 2019-12-01
Series:	Clinical Case Reports
Subjects:	acute myeloid leukemia allogeneic stem cell transplantation FLT3 mutation leukemia cutis relapse sorafenib
Online Access:	https://doi.org/10.1002/ccr3.2487

id	doaj-d2a2fdfe16cc4db1a5245e97a70467f3
record_format	Article
spelling	doaj-d2a2fdfe16cc4db1a5245e97a70467f32020-11-25T01:08:10ZengWileyClinical Case Reports2050-09042019-12-017122579258010.1002/ccr3.2487Sorafenib for relapsed FLT3‐ITD‐positive acute myeloid leukemia postallogeneic stem cell transplantation presenting as leukemia cutisRachel Brodie0Stephen E. Langabeer1John Quinn2Máirín E. McMenamin3Patrick J. Hayden4Department of Haematology St. James’s Hospital Dublin IrelandCancer Molecular Diagnostics St. James’s Hospital Dublin IrelandDepartment of Haematology Beaumont Hospital Dublin IrelandDepartment of Histopathology St. James’s Hospital Dublin IrelandDepartment of Haematology St. James’s Hospital Dublin IrelandAbstract Relapse of FLT3‐mutated acute myeloid leukemia (AML) following allogeneic stem cell transplantation is associated with poor survival. The clinical utility of sorafenib monotherapy in this setting is described in a patient presenting as leukemia cutis.https://doi.org/10.1002/ccr3.2487acute myeloid leukemiaallogeneic stem cell transplantationFLT3 mutationleukemia cutisrelapsesorafenib
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Rachel Brodie Stephen E. Langabeer John Quinn Máirín E. McMenamin Patrick J. Hayden
spellingShingle	Rachel Brodie Stephen E. Langabeer John Quinn Máirín E. McMenamin Patrick J. Hayden Sorafenib for relapsed FLT3‐ITD‐positive acute myeloid leukemia postallogeneic stem cell transplantation presenting as leukemia cutis Clinical Case Reports acute myeloid leukemia allogeneic stem cell transplantation FLT3 mutation leukemia cutis relapse sorafenib
author_facet	Rachel Brodie Stephen E. Langabeer John Quinn Máirín E. McMenamin Patrick J. Hayden
author_sort	Rachel Brodie
title	Sorafenib for relapsed FLT3‐ITD‐positive acute myeloid leukemia postallogeneic stem cell transplantation presenting as leukemia cutis
title_short	Sorafenib for relapsed FLT3‐ITD‐positive acute myeloid leukemia postallogeneic stem cell transplantation presenting as leukemia cutis
title_full	Sorafenib for relapsed FLT3‐ITD‐positive acute myeloid leukemia postallogeneic stem cell transplantation presenting as leukemia cutis
title_fullStr	Sorafenib for relapsed FLT3‐ITD‐positive acute myeloid leukemia postallogeneic stem cell transplantation presenting as leukemia cutis
title_full_unstemmed	Sorafenib for relapsed FLT3‐ITD‐positive acute myeloid leukemia postallogeneic stem cell transplantation presenting as leukemia cutis
title_sort	sorafenib for relapsed flt3‐itd‐positive acute myeloid leukemia postallogeneic stem cell transplantation presenting as leukemia cutis
publisher	Wiley
series	Clinical Case Reports
issn	2050-0904
publishDate	2019-12-01
description	Abstract Relapse of FLT3‐mutated acute myeloid leukemia (AML) following allogeneic stem cell transplantation is associated with poor survival. The clinical utility of sorafenib monotherapy in this setting is described in a patient presenting as leukemia cutis.
topic	acute myeloid leukemia allogeneic stem cell transplantation FLT3 mutation leukemia cutis relapse sorafenib
url	https://doi.org/10.1002/ccr3.2487
work_keys_str_mv	AT rachelbrodie sorafenibforrelapsedflt3itdpositiveacutemyeloidleukemiapostallogeneicstemcelltransplantationpresentingasleukemiacutis AT stephenelangabeer sorafenibforrelapsedflt3itdpositiveacutemyeloidleukemiapostallogeneicstemcelltransplantationpresentingasleukemiacutis AT johnquinn sorafenibforrelapsedflt3itdpositiveacutemyeloidleukemiapostallogeneicstemcelltransplantationpresentingasleukemiacutis AT mairinemcmenamin sorafenibforrelapsedflt3itdpositiveacutemyeloidleukemiapostallogeneicstemcelltransplantationpresentingasleukemiacutis AT patrickjhayden sorafenibforrelapsedflt3itdpositiveacutemyeloidleukemiapostallogeneicstemcelltransplantationpresentingasleukemiacutis
_version_	1725183806814552064

Sorafenib for relapsed FLT3‐ITD‐positive acute myeloid leukemia postallogeneic stem cell transplantation presenting as leukemia cutis

Similar Items